NEW YORK (GenomeWeb News) – Quest Diagnostics has received clinical laboratory approval from New York State for its ClariSure microarray-based comparative genomic hybridization post-natal test.

The ClariSure aCGH test was approved as an aid in detecting copy-number chromosomal abnormalities implicated in dozens of medical conditions including mental retardation, birth defects, and autism spectrum and developmental disorders, the Madison, NJ-based clinical lab firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.